STOCKCHASE

Stocks that under perform in a bull market tend to under perform more in a bear market. They have a decelerating growth rate. Expect there will be sales reduction over the next year.

2007-06-22

Comment

59.650

John Manley

From a technical perspective, he would look for it to carve out a double bottom, or a higher low.

2007-04-16

DON'T BUY

60.010

David Cockfield

Can't get enthused about the pharmaceutical markets. The amount of government action, the pressures, the lawsuits, etc. makes it a high-risk area.

2007-03-15

SELL

63.980

There are concerns that the growth level in the business indicates there has been a dissatisfaction and lack of interest in pharmaceutical and drug companies. Below the 200 day moving average.

2006-06-27

BUY

76.190

David Baskin

One of the great pharmaceutical stories. Fabulous company. The whole industry has been lackluster for last 2/3 years. This has been driven by patent litigation and lawsuits. Probably a reasonable price right now.

2006-02-01

BUY

75.200

The biotech sector has done well this year. This stock has held up well during the market correction. Looks like it has started into a longer climb higher. Because of the current market risk, you have to pick your entries.

2005-10-26

SELL

82.680

Kevin Vandermeer, B.Comm, CFA

Model price has been the same at $53.30. The increase in the stock price has been a little overdone.

2005-08-04

BUY

58.950

Ray Steele

Likes the stock. The sector has been weak over the last few months. Has a pretty full pipeline of stuff that could surprise us. Trades at a reasonable multple.

2005-03-17

DON'T BUY

59.810

Majority of money is from 3 products. Want's more diversificaion. Good balance sheet though.

2005-03-11

TOP PICK

54.360

Samuel D. Isaly

A very rapidly growing company. Earnings per share growth is in excess of 20% yearly. PE ratio barely more than that.

2004-08-13

TOP PICK

54.360

Nicholas Sargen

Likes the health-care sector. One of the top companies. Has underperformed for a long time, but they are willing to be patient.

2004-08-13

TOP PICK

55.730

Alan Blake

Under a cloud. Driven down because of generic drugs and imports from Canada. Medicare will be onerous. Powerful balance sheet.

2004-07-16

TOP PICK

56.650

Nicholas Sargen

Health care should outperform in a rising interest rate environment. A premier company. Likes the pipeline that it has. Out-of-favor right now.

2004-05-14

TOP PICK

57.140

(A top pick in Feb/04. Down a bit.) This sector has great prospects on a going forward basis but will be volatile on a short-term basis. A leader in their field. Good growth prospects.

2004-05-11

TOP PICK

59.510

Nicholas Sargen

2004-04-02

TOP PICK

62.760

A leading biotech company. Trading at 22 X next year's earnings. Pretty cheap for this quality of a company.

2004-03-09

BUY

61.870

A very mature biotech company. Expects about 10/15% revenue growth and about 20/25% earnings growth. Trading at a low multiple.

2003-12-29

PAST TOP PICK

61.150

(A top pick July 15/03. Down 13.7%.) Sold the stock in the summer.

2003-11-03

TOP PICK

61.190

Has made some good acquisitions in the last couple of years, which has propped up their product line. 25 X next year's earnings.

2003-11-03

BUY

60.300

Paul O'Neil

They don't have the problem of drugs going off patent. The stock can go much higher. Dropping currently because the sector is pulling it down.

2003-10-22

PAST TOP PICK

68.930

Was a top pick on Jun 4/03. Up 7%.) The leader in bio techs. Has grown its earnings every year since 1994.

2003-07-22

TOP PICK

71.540

A lot of drug products in the pipeline. Cash flow is growing.

2003-07-15

TOP PICK

67.210

Has made money every year going back to 1994. Good cash flow.

2003-07-02

TOP PICK

64.490

A safe way of investing in biotechs. Has held up through poor periods. Has a broad pipeline of products.

2003-06-04

BUY

61.880

Peter Arender, CFA

Has better earnings and price momentum than Biogen going forward. Likes both Biogen and Amgen, but Amgen is their first choice.

2003-05-26

PAST TOP PICK

60.970

(Was a top pick on Apr 7. Up 7.4%) Still likes.

2003-05-06

TOP PICK

61.300

Three drugs are coming out which are blockbusters.

2003-04-30

TOP PICK

58.410

Expects the S&P to drop to 820 and this stock could drop. Buy on pull backs. Has three block buster drugs on the way.

2003-04-07

BUY on WEAKNESS

51.520

Neil Murdock

Very successful biotech. Big growth. May be a little high.

2003-01-13

BUY on WEAKNESS

45.641

Andrew McCreath

18/20% growth for the next few years. Would prefer to buy in the $30's.

2002-08-13

HOLD

35.830

David Baskin

The biotech sector is down. A high quality company.

2002-07-03

DON'T BUY

56.400

Brad Willock

Doesn't like their run at Immunex.

2002-01-02

BUY on WEAKNESS

59.060

A little high now. Would buy at $50.

2001-12-28

DON'T BUY

58.330

Michelle Calpin

Too expensive.

2001-12-19

BUY

62.710

Gavin Graham

A good buy and hold. Good products. Volatile.

2001-07-31

BUY

57.160

Glenn Paradis, BA, CFA

Good broad spectrum. Volatile.

2001-07-06

PAST TOP PICK

68.200

(Was a top pick on Feb 22/01 down 3%)Still likes. A good entry point. Likes better than Hemasol.

2001-06-06

TOP PICK

70.063